I investigate the complex interplay between gut microbiota and cancer immunotherapy responses through integrated multi-omics approaches. My research combines shotgun metagenomics, comparative genomics and untargeted metabolomics with advanced artificial intelligence methodologies to identify microbial taxa and metabolic signatures that serve as predictive biomarkers for immune checkpoint inhibitor efficacy across multiple cancer types. ​My long-term objective is to develop precision medicine strategies and microbiota-modulation interventions to enhance patient responses, reduce treatment resistance, improve patient stratification and personalize therapeutic approaches.